DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed

Tuberculosis
T E TupasiD Urboda

Abstract

The Philippines, a high burden country for tuberculosis (TB). Health Operational Study. To describe preliminary data from the Makati Medical Center (MMC)-DOTS Plus pilot project. Patients were consecutively enrolled after confirmation of MDR-TB status. Individualized treatment regimens were based on drug susceptibility testing and history of previous intake for the other drugs that were not tested. Treatment outcome in those who had completed at least 18 months of therapy and interim outcome for those who received more than 12 months but less than 18 months were analyzed. One hundred forty-nine patients with MDR-TB were enrolled from April 1999 to 30 May 2002 at the MMC DOTS Clinic. Referrals were from private institutions and practicing physicians in 73.2% of cases. Approximately 30% of isolates tested were resistant to all five first-line drugs, 39.4% to four, 16.8% to three, 12.1% to two. Fluoroquinolone resistance was noted in 40.9% of all the isolates, including 54.5% of those resistant to five drugs and 34.6% of those resistant to four drugs. The outcome of 23 patients who completed therapy and 62 who have received more than 12 months therapy showed cure and likely cure in 73.4% of cases and failure in 3.8% and likely fai...Continue Reading

References

Oct 24, 2000·Tropical Medicine & International Health : TM & IH·C AuerM Weiss
Mar 16, 2002·Science·Christopher DyeMario C Raviglione
Apr 4, 2002·The Journal of Infectious Diseases·Christopher DyeBrian G Williams
May 10, 2002·The New England Journal of Medicine·Barry R Bloom

❮ Previous
Next ❯

Citations

Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christie Y JeonLaura E Via
Aug 8, 2009·American Journal of Respiratory and Critical Care Medicine·John Bernardo, Wing Wai Yew
Sep 7, 2012·PLoS Medicine·Shama D AhujaUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Feb 28, 2009·The Lancet Infectious Diseases·Evan W OrensteinAlison P Galvani
Feb 28, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Xun LeiShenglan Tang
Feb 3, 2009·Annals of Clinical Microbiology and Antimicrobials·Amina AbdelaalAmal Fathy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
V Bartu
International Journal of Antimicrobial Agents
Marie-Laure UffrediJérôme Robert
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Marcos BurgosCharles L Daley
Journal of Infection in Developing Countries
Jorge Zazueta-BeltranAdrián Canizalez-Roman
© 2022 Meta ULC. All rights reserved